Cargando…

P15-14. Assuring data quality of the phase III vaccine trial of ALVAC vaccine priming and AIDSVAX vaccine boosting in Thailand

Detalles Bibliográficos
Autores principales:	Kaewkungwal, J, Pitisuttithum, P, Nitayapan, S, Khamboonruang, C, Thongchareon, P, Kunasol, P, Benenson, M, Kim, J
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767710/ http://dx.doi.org/10.1186/1742-4690-6-S3-P215

Ejemplares similares

P14-05. Recruitment, retention and participation impact events among women participating in phase III community trial in Thailand
por: Pitisuttithum, P, et al.
Publicado: (2009)

Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2011)

ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone
por: Costanzo, Margaret C., et al.
Publicado: (2023)

OA04-06 LB. Post-infection cellular immune responses in recipients following ALVAC-HIV® + AIDSVAX® B/E prime-boost vaccination in the Thai Phase III Trial
por: Kim, JH, et al.
Publicado: (2009)

Ex Vivo Evaluation of Mucosal Responses to Vaccination with ALVAC and AIDSVAX of Non-Human Primates
por: Herrera, Carolina, et al.
Publicado: (2022)

Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial
por: Zolla-Pazner, Susan, et al.
Publicado: (2013)

Identification of Immunodominant CD4-Restricted Epitopes Co-Located with Antibody Binding Sites in Individuals Vaccinated with ALVAC-HIV and AIDSVAX B/E
por: Ratto-Kim, Silvia, et al.
Publicado: (2015)

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
por: de Souza, MS, et al.
Publicado: (2009)

Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency
por: Easterhoff, David, et al.
Publicado: (2020)

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials
por: Moodie, Zoe, et al.
Publicado: (2020)

Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs
por: Kim, Jaejo, et al.
Publicado: (2023)

Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
por: Banerjee, K, et al.
Publicado: (2012)

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults
por: Gray, Glenda E, et al.
Publicado: (2021)

Myeloid Cell Crosstalk Regulates the Efficacy of the DNA/ALVAC/gp120 HIV Vaccine Candidate
por: Vaccari, Monica, et al.
Publicado: (2019)

Can existing unrelated vaccines boost a COVID-19 vaccine prime?
por: Hupert, Nathaniel, et al.
Publicado: (2021)

Investigating Prime-Pull Vaccination through a Combination of Parenteral Vaccination and Intranasal Boosting
por: Roces, Carla B., et al.
Publicado: (2019)

Modeling the effect of boost timing in murine irradiated sporozoite prime-boost vaccines
por: Fernandez-Arias, Cristina, et al.
Publicado: (2018)

Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO)
por: McLeod, C., et al.
Publicado: (2023)

ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type
por: Schifanella, Luca, et al.
Publicado: (2019)

P19-51 LB. Improvement of the efficacy of ALVAC-HIV vaccine candidates for humans in non human primates
por: Franchini, G
Publicado: (2009)

A review of epidemic preparedness for influenza through local vaccine production: national security for Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2019)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
por: Robinson, HL, et al.
Publicado: (2009)

The efficacy of the prime-boost regimen for heterologous infectious bronchitis vaccines mandates the administration of homologous vaccines
por: Al-Kubati, Anwar A. G., et al.
Publicado: (2022)

Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2015)

Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type
por: Schifanella, Luca, et al.
Publicado: (2020)

A Double-Blind Randomized Phase I Clinical Trial Targeting ALVAC-HIV Vaccine to Human Dendritic Cells
por: Eller, Michael A., et al.
Publicado: (2011)

The Effect of Therapeutic HIV Vaccination With ALVAC-HIV With or Without Remune on the Size of the Viral Reservoir (A CTN 173 Substudy)
por: Angel, Jonathan B., et al.
Publicado: (2015)

The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination
por: Tomalka, Jeffrey Alan, et al.
Publicado: (2021)

A Heterologous Prime/Boost Vaccination Strategy Enhances the Immunogenicity of Therapeutic Vaccines for Hepatitis C Virus
por: Fournillier, Anne, et al.
Publicado: (2013)

Prime-Boost Vaccination With Covaxin/BBV152 Induces Heightened Systemic Cytokine and Chemokine Responses
por: Kumar, Nathella Pavan, et al.
Publicado: (2021)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022)

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
por: Shaw, Robert H, et al.
Publicado: (2021)

Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

Optimization and validation of an ELISA assay for the determination of antibody responses to CN54gp140 and AIDSVAX BE for use in the Phase IIb PrEPVacc vaccine trial
por: Gombe, Ben, et al.
Publicado: (2022)

Prime-boost, double-dose influenza vaccine immunity in COPD: a pilot observational study
por: Anderson, Gary P., et al.
Publicado: (2023)

Priming with a DNA vaccine and boosting with an inactivated vaccine enhance the immune response against infectious bronchitis virus
por: Guo, Zicheng, et al.
Publicado: (2010)

Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates
por: van Doremalen, Neeltje, et al.
Publicado: (2021)

Immunogenicity of low dose prime-boost vaccination of mRNA vaccine CV07050101 in non-human primates
por: van Doremalen, Neeltje, et al.
Publicado: (2021)

Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates
por: Luo, Shengxue, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9fsfarhhsf0if7ufrju1lme9i5